Spoken Alpha
MetaVia Inc.
MetaVia develops novel pharmaceuticals to treat cardiometabolic diseases, with two lead programs: vanoglipel (DA-1241), a GPR119 agonist in Phase 2a trials for metabolic dysfunction-associated steatohepatitis and Type 2 diabetes, and DA-1726, a GLP-1/glucagon receptor dual agonist in Phase 1 trials for obesity.
MetaVia Inc is a Healthcare company operating in Biotechnology with a $10.3M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add MTVA, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MTVA.
$ curl https://api.spokenalpha.com/v1/companies/MTVAFAQ
Spoken Alpha indexes MTVA's earnings call transcripts at https://spokenalpha.com/companies/MTVA. Each call links to attributed speakers and parsed analyst Q&A. MetaVia Inc.'s own investor relations page is at https://ir.metaviatx.com/.
MetaVia Inc. (MTVA) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.94 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.90 | $-0.85 | -5.9% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-0.79 | $-0.75 | -5.3% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | — | $-1.82 | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-1.54 | $-2.75 | +44.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.26 | $-0.32 | +18.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-0.36 | $-0.30 | -20.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-19 | $-3.52 | $-8.14 | +56.8% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-6.05 | $-8.03 | +24.7% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-20.35 | $-12.36 | -64.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-1.32 | $-3.63 | +63.6% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-25.08 | $-8.63 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-7.92 | $-9.68 | +18.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-1.76 | $-11.44 | +84.6% | — | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-5.28 | $-55.44 | +90.5% | — | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $4.93 | $-1.20 | +100.0% | — | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-308.00 | $-448.80 | +31.4% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-15 | $-0.12 | $-5.10 | +97.7% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-24 | $-0.17 | $-0.16 | -6.3% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-422.40 | $-475.20 | +11.1% | — | — | — | EODHD |
Source: EODHD. MTVA reported actuals as published; sparse fields render as —.